Global Oral Anticoagulant

Oral Anticoagulant Comprehensive Study by Type (Warfarin, Dabigatran, Rivaroxaban, Others), Application (Thromboembolic Disease, Disseminated Intravascular Coagulation, Cardiovascular Surgery, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Retail Pharmacies) Players and Region - Global Market Outlook to 2026

Oral Anticoagulant Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Oral Anticoagulant Market?

Oral anticoagulants have been used by clinicians in patients with the thrombotic disease, particularly for stroke prevention in AF. A growing number of direct oral anticoagulants presented for clinical use has kept the oral anticoagulant market lucrative for developers of such agents. A growing number of studies, including randomized clinical trials, have focused on evaluating their effectiveness and effectiveness against vitamin K antagonists. The recent introduction of non-vitamin K-dependent oral anticoagulants has also helped fuel the new development avenues of the oral anticoagulant market. Atrial fibrillation and venous thromboembolism are among the top indications that have generated market revenue. However, sufficient data on pharmacokinetics and pharmacodynamics are lacking, resulting in a weak evidence base. The Oral Anticoagulant Market sheds light on the above trends and offers trends that will drive their clinical acceptance in treating various types of patients. The entire development path of the last decades is examined more closely. The evaluation also sheds light on the large studies that have focused on evaluating new routes of administration to increase efficacy.

The market study is being classified by Type (Warfarin, Dabigatran, Rivaroxaban and Others), by Application (Thromboembolic Disease, Disseminated Intravascular Coagulation, Cardiovascular Surgery and Others) and major geographies with country level break-up.

Boehringer Ingelheim (Germany), Bristol Myers Squibb (United States), Johnson & Johnson (United States), Sanofi (France), Pfizer Inc. (United States), AstraZeneca (United Kingdom), Bayer (Germany), Cellceutix Corporation (United States), Cosmo Pharmaceuticals (Ireland), CSL Behring (United States), Eisai (Japan), GSK (United Kingdom), Valeant Pharmaceuticals (United States) and The Medicines Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Urigen Pharmaceuticals, Inc. (United States), Sagent Pharmaceuticals (United States) and Daiichi Sankyo (Japan).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oral Anticoagulant market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Oral Anticoagulant market by Type, Application and Region.

On the basis of geography, the market of Oral Anticoagulant has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • A Growing Numbers of Direct Oral Anticoagulants Unveiled For Clinical Use
  • A Growing Body of Studies, Including Randomized Clinical Trials
  • Growing Patients with Deep Vein Thrombosis

Market Trend
  • The Prevalence of Cardiac Arrhythmia
  • Rise in Number of Laboratory Developed Tests
  • Growing Prevalence of Diseases Coupled With High Intake of NOACs

Restraints
  • Higher Medication Costs Contrasted and Warfarin

Opportunities
  • The Growing Acceptance of Anticoagulant Therapy in Medical and Surgical Units
  • The Growing Number of Target-Specific Oral Anticoagulants Is Unlocking New Avenues in the Oral Anticoagulant Market

Challenges
  • Rising Regulatory Scenario





Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Oral Anticoagulant, Government Regulatory and Research Organizations and End-Use Industries

Report Objectives / Segmentation Covered

By Type
  • Warfarin
  • Dabigatran
  • Rivaroxaban
  • Others
By Application
  • Thromboembolic Disease
  • Disseminated Intravascular Coagulation
  • Cardiovascular Surgery
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Growing Numbers of Direct Oral Anticoagulants Unveiled For Clinical Use
      • 3.2.2. A Growing Body of Studies, Including Randomized Clinical Trials
      • 3.2.3. Growing Patients with Deep Vein Thrombosis
    • 3.3. Market Challenges
      • 3.3.1. Rising Regulatory Scenario
    • 3.4. Market Trends
      • 3.4.1. The Prevalence of Cardiac Arrhythmia
      • 3.4.2. Rise in Number of Laboratory Developed Tests
      • 3.4.3. Growing Prevalence of Diseases Coupled With High Intake of NOACs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Anticoagulant, by Type, Application, Distribution Channel and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Oral Anticoagulant (Value)
      • 5.2.1. Global Oral Anticoagulant by: Type (Value)
        • 5.2.1.1. Warfarin
        • 5.2.1.2. Dabigatran
        • 5.2.1.3. Rivaroxaban
        • 5.2.1.4. Others
      • 5.2.2. Global Oral Anticoagulant by: Application (Value)
        • 5.2.2.1. Thromboembolic Disease
        • 5.2.2.2. Disseminated Intravascular Coagulation
        • 5.2.2.3. Cardiovascular Surgery
        • 5.2.2.4. Others
      • 5.2.3. Global Oral Anticoagulant by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Drug Stores
        • 5.2.3.4. Retail Pharmacies
      • 5.2.4. Global Oral Anticoagulant Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Oral Anticoagulant (Price)
      • 5.3.1. Global Oral Anticoagulant by: Type (Price)
  • 6. Oral Anticoagulant: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boehringer Ingelheim (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cellceutix Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cosmo Pharmaceuticals (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CSL Behring (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eisai (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GSK (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Valeant Pharmaceuticals (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. The Medicines Company (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Oral Anticoagulant Sale, by Type, Application, Distribution Channel and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Oral Anticoagulant (Value)
      • 7.2.1. Global Oral Anticoagulant by: Type (Value)
        • 7.2.1.1. Warfarin
        • 7.2.1.2. Dabigatran
        • 7.2.1.3. Rivaroxaban
        • 7.2.1.4. Others
      • 7.2.2. Global Oral Anticoagulant by: Application (Value)
        • 7.2.2.1. Thromboembolic Disease
        • 7.2.2.2. Disseminated Intravascular Coagulation
        • 7.2.2.3. Cardiovascular Surgery
        • 7.2.2.4. Others
      • 7.2.3. Global Oral Anticoagulant by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Drug Stores
        • 7.2.3.4. Retail Pharmacies
      • 7.2.4. Global Oral Anticoagulant Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Oral Anticoagulant (Price)
      • 7.3.1. Global Oral Anticoagulant by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Anticoagulant: by Type(USD Million)
  • Table 2. Oral Anticoagulant Warfarin , by Region USD Million (2015-2020)
  • Table 3. Oral Anticoagulant Dabigatran , by Region USD Million (2015-2020)
  • Table 4. Oral Anticoagulant Rivaroxaban , by Region USD Million (2015-2020)
  • Table 5. Oral Anticoagulant Others , by Region USD Million (2015-2020)
  • Table 6. Oral Anticoagulant: by Application(USD Million)
  • Table 7. Oral Anticoagulant Thromboembolic Disease , by Region USD Million (2015-2020)
  • Table 8. Oral Anticoagulant Disseminated Intravascular Coagulation , by Region USD Million (2015-2020)
  • Table 9. Oral Anticoagulant Cardiovascular Surgery , by Region USD Million (2015-2020)
  • Table 10. Oral Anticoagulant Others , by Region USD Million (2015-2020)
  • Table 11. Oral Anticoagulant: by Distribution Channel(USD Million)
  • Table 12. Oral Anticoagulant Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Oral Anticoagulant Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Oral Anticoagulant Drug Stores , by Region USD Million (2015-2020)
  • Table 15. Oral Anticoagulant Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. South America Oral Anticoagulant, by Country USD Million (2015-2020)
  • Table 17. South America Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 18. South America Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 19. South America Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 21. Brazil Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 22. Brazil Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 23. Argentina Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 24. Argentina Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 25. Argentina Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 26. Rest of South America Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 29. Asia Pacific Oral Anticoagulant, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 33. China Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 34. China Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 35. China Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 36. Japan Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 37. Japan Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 38. Japan Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 39. India Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 40. India Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 41. India Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 42. South Korea Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 43. South Korea Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 44. South Korea Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 45. Taiwan Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 46. Taiwan Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 47. Taiwan Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 48. Australia Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 49. Australia Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 50. Australia Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 54. Europe Oral Anticoagulant, by Country USD Million (2015-2020)
  • Table 55. Europe Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 56. Europe Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 57. Europe Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 58. Germany Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 59. Germany Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 60. Germany Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 61. France Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 62. France Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 63. France Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 64. Italy Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 65. Italy Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 66. Italy Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 67. United Kingdom Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 70. Netherlands Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 71. Netherlands Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 72. Netherlands Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Europe Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 76. MEA Oral Anticoagulant, by Country USD Million (2015-2020)
  • Table 77. MEA Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 78. MEA Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 79. MEA Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 80. Middle East Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 81. Middle East Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 82. Middle East Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 83. Africa Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 84. Africa Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 85. Africa Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 86. North America Oral Anticoagulant, by Country USD Million (2015-2020)
  • Table 87. North America Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 88. North America Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 89. North America Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 90. United States Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 91. United States Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 92. United States Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 93. Canada Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 94. Canada Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 95. Canada Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 96. Mexico Oral Anticoagulant, by Type USD Million (2015-2020)
  • Table 97. Mexico Oral Anticoagulant, by Application USD Million (2015-2020)
  • Table 98. Mexico Oral Anticoagulant, by Distribution Channel USD Million (2015-2020)
  • Table 99. Oral Anticoagulant: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Oral Anticoagulant: by Type(USD Million)
  • Table 115. Oral Anticoagulant Warfarin , by Region USD Million (2021-2026)
  • Table 116. Oral Anticoagulant Dabigatran , by Region USD Million (2021-2026)
  • Table 117. Oral Anticoagulant Rivaroxaban , by Region USD Million (2021-2026)
  • Table 118. Oral Anticoagulant Others , by Region USD Million (2021-2026)
  • Table 119. Oral Anticoagulant: by Application(USD Million)
  • Table 120. Oral Anticoagulant Thromboembolic Disease , by Region USD Million (2021-2026)
  • Table 121. Oral Anticoagulant Disseminated Intravascular Coagulation , by Region USD Million (2021-2026)
  • Table 122. Oral Anticoagulant Cardiovascular Surgery , by Region USD Million (2021-2026)
  • Table 123. Oral Anticoagulant Others , by Region USD Million (2021-2026)
  • Table 124. Oral Anticoagulant: by Distribution Channel(USD Million)
  • Table 125. Oral Anticoagulant Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 126. Oral Anticoagulant Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 127. Oral Anticoagulant Drug Stores , by Region USD Million (2021-2026)
  • Table 128. Oral Anticoagulant Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 129. South America Oral Anticoagulant, by Country USD Million (2021-2026)
  • Table 130. South America Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 131. South America Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 132. South America Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 133. Brazil Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 134. Brazil Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 135. Brazil Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 136. Argentina Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 137. Argentina Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 138. Argentina Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 139. Rest of South America Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 140. Rest of South America Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 141. Rest of South America Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 142. Asia Pacific Oral Anticoagulant, by Country USD Million (2021-2026)
  • Table 143. Asia Pacific Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 144. Asia Pacific Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 145. Asia Pacific Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 146. China Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 147. China Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 148. China Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 149. Japan Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 150. Japan Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 151. Japan Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 152. India Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 153. India Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 154. India Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 155. South Korea Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 156. South Korea Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 157. South Korea Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 158. Taiwan Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 159. Taiwan Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 160. Taiwan Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 161. Australia Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 162. Australia Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 163. Australia Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 167. Europe Oral Anticoagulant, by Country USD Million (2021-2026)
  • Table 168. Europe Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 169. Europe Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 170. Europe Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 171. Germany Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 172. Germany Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 173. Germany Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 174. France Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 175. France Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 176. France Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 177. Italy Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 178. Italy Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 179. Italy Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 180. United Kingdom Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 181. United Kingdom Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 182. United Kingdom Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 183. Netherlands Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 184. Netherlands Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 185. Netherlands Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 186. Rest of Europe Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 187. Rest of Europe Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 188. Rest of Europe Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 189. MEA Oral Anticoagulant, by Country USD Million (2021-2026)
  • Table 190. MEA Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 191. MEA Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 192. MEA Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 193. Middle East Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 194. Middle East Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 195. Middle East Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 196. Africa Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 197. Africa Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 198. Africa Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 199. North America Oral Anticoagulant, by Country USD Million (2021-2026)
  • Table 200. North America Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 201. North America Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 202. North America Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 203. United States Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 204. United States Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 205. United States Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 206. Canada Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 207. Canada Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 208. Canada Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 209. Mexico Oral Anticoagulant, by Type USD Million (2021-2026)
  • Table 210. Mexico Oral Anticoagulant, by Application USD Million (2021-2026)
  • Table 211. Mexico Oral Anticoagulant, by Distribution Channel USD Million (2021-2026)
  • Table 212. Oral Anticoagulant: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Anticoagulant: by Type USD Million (2015-2020)
  • Figure 5. Global Oral Anticoagulant: by Application USD Million (2015-2020)
  • Figure 6. Global Oral Anticoagulant: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Oral Anticoagulant Share (%), by Country
  • Figure 8. Asia Pacific Oral Anticoagulant Share (%), by Country
  • Figure 9. Europe Oral Anticoagulant Share (%), by Country
  • Figure 10. MEA Oral Anticoagulant Share (%), by Country
  • Figure 11. North America Oral Anticoagulant Share (%), by Country
  • Figure 12. Global Oral Anticoagulant: by Type USD/Units (2015-2020)
  • Figure 13. Global Oral Anticoagulant share by Players 2020 (%)
  • Figure 14. Global Oral Anticoagulant share by Players (Top 3) 2020(%)
  • Figure 15. Global Oral Anticoagulant share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 19. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2020
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 27. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer (Germany) Revenue: by Geography 2020
  • Figure 31. Cellceutix Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cellceutix Corporation (United States) Revenue: by Geography 2020
  • Figure 33. Cosmo Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Cosmo Pharmaceuticals (Ireland) Revenue: by Geography 2020
  • Figure 35. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 36. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 37. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Eisai (Japan) Revenue: by Geography 2020
  • Figure 39. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Valeant Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 42. Valeant Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 43. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. The Medicines Company (United States) Revenue: by Geography 2020
  • Figure 45. Global Oral Anticoagulant: by Type USD Million (2021-2026)
  • Figure 46. Global Oral Anticoagulant: by Application USD Million (2021-2026)
  • Figure 47. Global Oral Anticoagulant: by Distribution Channel USD Million (2021-2026)
  • Figure 48. South America Oral Anticoagulant Share (%), by Country
  • Figure 49. Asia Pacific Oral Anticoagulant Share (%), by Country
  • Figure 50. Europe Oral Anticoagulant Share (%), by Country
  • Figure 51. MEA Oral Anticoagulant Share (%), by Country
  • Figure 52. North America Oral Anticoagulant Share (%), by Country
  • Figure 53. Global Oral Anticoagulant: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Boehringer Ingelheim (Germany)
  • Bristol Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • Sanofi (France)
  • Pfizer Inc. (United States)
  • AstraZeneca (United Kingdom)
  • Bayer (Germany)
  • Cellceutix Corporation (United States)
  • Cosmo Pharmaceuticals (Ireland)
  • CSL Behring (United States)
  • Eisai (Japan)
  • GSK (United Kingdom)
  • Valeant Pharmaceuticals (United States)
  • The Medicines Company (United States)
Additional players considered in the study are as follows:
Urigen Pharmaceuticals, Inc. (United States) , Sagent Pharmaceuticals (United States) , Daiichi Sankyo (Japan)
Select User Access Type

Key Highlights of Report


Jun 2021 207 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oral Anticoagulant Quantitative research analysis
Global Oral Anticoagulant Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"A Growing Numbers of Direct Oral Anticoagulants Unveiled For Clinical Use " is seen as one of major growth factors of Oral Anticoagulant Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
will lead the Oral Anticoagulant Market.

Know More About Global Oral Anticoagulant Report?

Have a Query? Click Here

Other Related Reports

Primary Cells Comprehensive Study by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Researc...
$ 3350
Central Nervous System Comprehensive Study by Drugs (Biologic, Non- Biologic), Disease (Infectious Diseases, Neurodegenerative Diseases, Autoimmune and Inflammatory Diseases, Genetic Disorders, Cance...
$ 3450
Human Growth Hormone Comprehensive Study by Type (Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (rhGH)), Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stat...
$ 3450
Endobronchial Ultrasound Biopsy Comprehensive Study by Type (Biopsy Forceps, Cytology Brushes, Biopsy Needles, Transbronchial Aspiration Needles, Spray Catheters, Others), Application (Infection Diag...
$ 3650
Chamomile Oil Comprehensive Study by Type (High-Quality, Middle-Quality, Low-Quality), Application (Essential Oils, Other), Nature (Organic Chamomile Essential Oil, Conventional Chamomile Essential O...
$ 3450
Drugs of Abuse Testing Comprehensive Study by Type (Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers), Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devi...
$ 3750